알보테크 (ALVO) 주가

알보테크(ALVO)는 NAS에 상장된 Healthcare · Drug Manufacturers - Specialty & Generic 기업입니다. 현재가 $5.87 (+9.93%), 시가총액 $1.12B, PER 35.90, 52주 범위 $3.11 ~ $11.45.

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a…

핵심 지표

• 현재가: $5.87 (+9.93%)
• 시가총액: $1.12B
• PER (주가수익비율): 35.90
• 52주 최저~최고: $3.11 ~ $11.45
• 섹터: Healthcare
• 산업: Drug Manufacturers - Specialty & Generic
• 거래소: NAS

알보테크의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.

알보테크 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 매수 (4.0 / 5)

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 0.00
• 순이익률: -14.36%
• 영업이익률: 9.13%

자주 묻는 질문